obinutuzumab

E2190199 UNEXPLORED

Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody used primarily in the treatment of certain B‑cell malignancies such as chronic lymphocytic leukemia and follicular lymphoma.

Try in SPARQL Jump to: Surface forms Referenced by

All labels observed (1)

Label	Occurrences
obinutuzumab canonical	1

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

MS4A1 → targetOfDrug → obinutuzumab ⓘ

subject linked to: MS4A1 gene